Icoria to Conduct Biomarker Study for Isis Pharmaceuticals
Icoria, Inc. announced that it has signed an agreement with Isis Pharmaceuticals to identify biomarkers of toxicity in animal models. Icoria will use its metabolomics platform to characterize differences in biochemical profiles between treated and untreated animal subjects and to identify those biochemicals that are specifically affected by treatment. Isis can use this information to suggest pathways that may be altered by future drug candidates.
Metabolomics, or biochemical profiling, uses mass spectrometry to measure net changes in the level of the body's endogenous biochemicals, such as amino acids, sugars and fatty acids, and provides a means of evaluating drug action and disease state. When combined with proprietary software developed by Icoria, this technology enables Icoria to construct biomarkers that can detect toxicity or the therapeutic effects of drugs. Drug development companies such as Isis can use this data to infer pathway-based mechanisms of drug action and patient response, and to assess drug safety.
Financial details of the agreement were not disclosed, however, it is not expected to significantly impact the company's recently released financial statements.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!